Seyhmus Kavak

Dr. Seyhmus Kavak

radiology, Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi, Diyarbakır, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2012 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
BABilgin Kadri Aribaş
Bilgin Kadri Aribaş
KAKemal Arda
Kemal Arda
ÖAÖzge Aribaş
Özge Aribaş
NÇNazan Çiledağ
Nazan Çiledağ
ZYZeynel Yoloğlu
Zeynel Yoloğlu
ETEkrem Tekin
Ekrem Tekin
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

18 March 2022 in BMC Medical Imaging
Verified
Journal Article
Open access
PDF file
SKSeyhmus Kavak
Seyhmus Kavak
SKSafak Kaya
Safak Kaya
ASAyhan Senol
Ayhan Senol
NSNilgun Sogutcu
Nilgun Sogutcu
Background: The aims of this study were to evaluate liver fibrosis with two-dimensional (2D) shear wave elastography (SWE) in patients with chronic hepatitis B (CHB), to compare 2D-SWE with histopathology and to determine the change in liver stiffness values after antiviral therapy. Material and methods: A total of 253 patients with CHB were included in this prospective study. 2D-SWE with propagation map guidance to measure liver stiffness, fibrosis-4 index (FIB-4) and aspartate aminotransferase to platelet ratio index (APRI) scoring and additional liver biopsy were performed in patients with CHB. Liver stiffness was measured again at 24 and 48 weeks in all patients. The Spearman rank correlation test was used to analyse the correlation between variables, and receiver operating curve analysis was used to evaluate the diagnostic performance in terms of fibrosis. Results: Liver stiffness measurements made with 2D-SWE demonstrated a significant positive correlation with the fibrosis stage and FIB-4 score (rs = 0.774 and 0.337, respectively, p < 0.001 for both). The area under the curve value for kPa for the prediction of significant fibrosis was 0.956 (95% CIs) (0.920–0.991), and the optimal cut-off value was 8.2 kPa (sensitivity: 92.7% and specificity: 78.9%); these values were 0.978 (95% CIs, 0.945–1.000) and 10.1 kPa (sensitivity: 92.9% and specificity: 96.4%) for the prediction of severe fibrosis. After antiviral treatment, a decrease in liver stiffness values measured by 2D-SWE was detected (mean kPa values at 0 and 48 weeks; 9.24 and 7.36, respectively, p < 0.001). Conclusion: In conclusion, the measurement of liver stiffness with 2D-SWE has high diagnostic performance in the determination of hepatic fibrosis and can be used to evaluate the response to treatment in patients receiving antiviral therapy.

8 February 2021 in Renal Failure
Verified
Journal Article
Open access
EGEmrah Günay
Emrah Günay
GKGunay Kozan
Gunay Kozan
EYEnver Yuksel
Enver Yuksel
AMAyser Mizrakli
Ayser Mizrakli
OAOzgur Aslan
Ozgur Aslan
ZYZulfukar Yilmaz
Zulfukar Yilmaz
Dear Editor, Sudden hearing loss in cases of SARS-CoV-2 is rare, and it is even less common as a first symptom. For the first time in the literature, we present a case of SARS-CoV-2 accompanied by ...

1 November 2021 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
SKSafak Kaya
Safak Kaya
SKSehmuz Kaya
Sehmuz Kaya
SKSeyhmus Kavak
Seyhmus Kavak
SCSenol Comoglu
Senol Comoglu
Objective: Spondylodiscitis is an important clinical a problem requiring serious approaches. In this study, we sought to raise awareness by examining the epidemiology and laboratory, clinical, and radiological findings of spondylodiscitis, which sometimes has a delayed diagnosis and which can be difficult to treat. Methods: In total, 343 patients with spondylodiscitis were included in the study. Results: The patients were classified as having as pyogenic (n = 153, 44.6%), brucellar (n = 138, 40.2%), or tuberculous (n = 52, 15.2%) spondylodiscitis. Meanwhile, 281 patients underwent magnetic resonance imaging, 71 underwent computed tomography, and 17 underwent scintigraphy for diagnosis. The rates of involvement at more than two segments and paraspinal abscess were significantly higher in tuberculous spondylodiscitis. However, disc involvement was significantly more common in brucellar and pyogenic spondylodiscitis. Conclusion: The incidence of spondylodiscitis has increased substantially, especially in the young population. The invasive procedures and high rate of culture negativity make the diagnosis difficult. Therefore, clinical and radiological findings are useful in the diagnosis of spondylodiscitis. Despite the high rate of culture negativity, every effort should be made to identify the causative organism using invasive methods.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SKSafak Kaya
Safak Kaya
SKSeyhmus Kavak
Seyhmus Kavak
Background. Cytokine release syndrome can be observed during the course of COVID‐19. Tocilizumab is used for treating this highly fatal syndrome. We think that the starting time of tocilizumab is important. In this article, we aimed to discuss the efficacy of tocilizumab and to review the necessity of starting it in the early period and the laboratory values that guide us in determining the time of this early period. Methods. This retrospective study includes a total of 308 patients with a diagnosis of COVID‐19 who were treated with tocilizumab, who were hospitalized in the University of Health Sciences, Gazi Yaşargil Training and Research Hospital between July 2020 and December 2020. The data of the patients were recorded on the day of hospitalization, the day of taking tocilizumab (day 0), and the 1st day, 3rd day, 7th day, and 14th day after taking tocilizumab. Data included age, gender, underlying diseases, where the patient was followed, duration of symptoms before admission to the hospital, duration of oxygen demand before tocilizumab, fever, saturation, and laboratory values. Patients were divided into the mortality group (group 1) and the survival group (group 2), and all data were compared. Results. The study consisted of 308 COVID‐19 patients divided into two groups: the mortality group (group 1, n = 135) and the survival group (group 2, n = 173). The median age of the patients was 60 (min–max: 50‐70) years, 75.3% (n = 232) were male, and 56.8% had at least one comorbidity. While 88.9% of group 1 was in the intensive care unit, 26.6% of group 2 received tocilizumab while in the intensive care unit, and there was a statistically significant difference. Median SpO2 values and lymphocyte counts were significantly lower in group 1 than in group 2, both on the day of hospitalization and on the day of the first dose of tocilizumab treatment (p < 0.001 for both). C‐reactive protein, d‐dimer, and alanine aminotransferase values were higher in the mortal group on the first day of hospitalization, and this was significant (p = 0.021, p = 0.001, and p = 0.036, respectively). In our study, d‐dimer was 766.5 ng/mL in the survivor group and 988.5 ng/mL in the mortal group. In our patient group, the mean lymphocyte count was 700 × 103/mm3 in the group that survived the first day of TCZ and 500 × 103/mm3 in the mortal group. In addition, the CRP value was 135.5 mg/L in the survivor group and 169 mg/L in the mortal group. There was no difference between ferritin values. Conclusions. Tocilizumab is still among the COVID‐19 treatment options and appears to be effective. But the start time is important. In order to increase its effectiveness, it may be important to know a cut‐off value of the laboratory findings required for the diagnosis of cytokine release syndrome. Further studies are needed for this.

4 October 2021 in BMC Medical Imaging
Verified
Journal Article
Open access
PDF file
SKSeyhmus Kavak
Seyhmus Kavak
RDRecai Duymus
Recai Duymus
Background: This study aimed to compare the performance and interobservers agreement of cases with findings on chest CT based on the British Society of Thoracic Imaging (BSTI) guideline statement of COVID-19 and the Radiological Society of North America (RSNA) expert consensus statement. Methods: In this study, 903 patients who had admitted to the emergency department with a pre-diagnosis of COVID-19 between 1 and 18 July 2020 and had chest CT. Two radiologists classified the chest CT findings according to the RSNA and BSTI consensus statements. The performance, sensitivity and specificity values of the two classification systems were calculated and the agreement between the observers was compared by using kappa analysis. Results: Considering RT-PCR test result as a gold standard, the sensitivity, specificity and positive predictive values were significantly higher for the two observers according to the BSTI guidance statement and the RSNA expert consensus statement (83.3%, 89.7%, 89.0%; % 81.2,% 89.7,% 88.7, respectively). There was a good agreement in the PCR positive group (κ: 0.707; p < 0.001 for BSTI and κ: 0.716; p < 0.001 for RSNA), a good agreement in the PCR negative group (κ: 0.645; p < 0.001 for BSTI and κ: 0.743; p < 0.001 for RSNA) according to the BSTI and RSNA classification between the two radiologists. Conclusion: As a result, RSNA and BSTI statement provided reasonable performance and interobservers agreement in reporting CT findings of COVID-19. However, the number of patients defined as false negative and indeterminate in both classification systems is at a level that cannot be neglected.